Transthera Sciences received NMPA approval in China for Yochanra (tinengotinib), a treatment for FGFR2-positive cholangiocarcinoma that has progressed after prior FGFR inhibitor therapy. The approval creates a post-targeted-therapy option for patients who have exhausted medicines that reshaped care for molecularly defined biliary cancers. The product is intended to address a continuing clinical gap in advanced cholangiocarcinoma, where resistance to first-line or subsequent FGFR-directed regimens frequently limits durable benefit. For developers with targeted oncology portfolios, the NMPA decision signals continued regulatory receptivity to line-of-therapy specific oncology strategies, particularly where earlier biomarker-defined options have already established treatment frameworks.